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Epilepsy is a disorder characterized by seizures and convulsions. The basis of epilepsy
is an increase in neuronal excitability that, in some cases, may be caused by functional
defects in neuronal voltage gated sodium channels (NaVs). The C121W mutation of the β1
subunit, in particular, gives rise to the thermosensitive generalized epilepsy with febrile
seizures plus (GEFS+) phenotype. Lacosamide is used to treat epileptic seizures and
is distinct from other anti-seizure drugs by targeting NaV slow-inactivation. We studied
the effects of a physiologically relevant concentration of lacosamide on the biophysical
properties of NaV1.2 channels associated with either WT-β1 or the mutant C121W-β1
subunit. Biophysical parameters were measured at both normal (22◦C) and elevated (34◦C)
temperatures to elicit the differential temperature-sensitivity of C121W. Lacosamide was
more effective in NaV1.2 associated with the WT-β1 than with C121W-β1 at either
temperature. There is also a more potent effect by lacosamide on slow inactivation at
elevated temperatures. Our data suggest a modulatory role is imparted by the β1 subunit
in the interaction between the drug and the channel.
Keywords: voltage-gated sodium channels, slow inactivation, lacosamide, GEFS+, thermosensitive, WT-β1
(wild-type), C121W-β1
INTRODUCTION
Epilepsy is a neurological disorder in which neuronal hyperex-
citability causes convulsions and seizures. This disorder may be
elicited via different mechanisms, some of which have genetic
origins. There are over 150 described epileptogenic mutations in
the NaV1.1 isoform of the voltage-gated sodium channel (NaV),
which is expressed in the central nervous system (Clare et al.,
2000; Meisler and Kearney, 2005; Mantegazza et al., 2010). Eight
epileptogenic mutations are associated with NaV1.2 (Meisler
and Kearney, 2005). Several mutations/deletions in the auxil-
iary β1 subunit give rise to generalized epilepsy with febrile
seizures plus (GEFS+) (Wallace et al., 1998; Audenaert et al.,
2003; Xu et al., 2007). The C121W-β1 was the first of such
mutations to be described (Wallace et al., 1998; Wimmer et al.,
2010), and causes channel hyperexcitabilty at elevated temper-
atures. It was later demonstrated that the kinetics of recovery
from the fast-inactivated state is enhanced at elevated temper-
atures (34◦C) when the C121W-β1 mutation is co-expressed
with NaV1.2 (Egri et al., 2012). The WT-β1 subunit thus
appears to have a thermoprotective function that is lost in
C121W-β1.
Two classes of anticonvulsants act on different time-scales
of inactivation in neuronal NaVs. The classic anticonvulsants,
including phenytoin, carbamazepine, and lamotrigine, stabilize
the fast-inactivated state (Ragsdale et al., 1996; Ragsdale and
Avoli, 1998; Lees and Shipton, 2009; Karoly et al., 2010). In
fast inactivation, the IFMT motif in the cytoplasmic linker
between domains III and IV occludes the pore of the channel
in the millisecond time scale via thermodynamically favorable
interactions with the inner vestibule of the channel (Ragsdale and
Avoli, 1998; Clare et al., 2000; Denac et al., 2000; Yu et al., 2005;
Catterall et al., 2012). Classic anticonvulsants bind within the
inner vestibule of the channel forming interactions with the IFMT
and fast-inactivation binding sites of the IFMT motif (Ragsdale
and Avoli, 1998). A novel class of anticonvulsants, including
lacosamide, act by a different mechanism to stabilize the slow-
inactivated state of NaV s (Errington et al., 2008; Sheets et al.,
2008; Lees and Shipton, 2009). Slow inactivation occurs over a
hundred-milliseconds to seconds time scale through a combina-
tion of conformational rearrangements in the pore region and
long distance interactions with other channel structures (O’reilly
et al., 1999; Ong et al., 2000; McCollum et al., 2003; Zhang et al.,
2003).
We tested the effects of lacosamide on NaV1.2 co-expressed
with both WT-β1and C121W-β1 subunits, at normal (22◦C) and
elevated temperatures (34◦C) to mimic the temperature sensitiv-
ity of GEFS+. We find the efficacy of lacosamide is lost with the
C121W-β1 mutation. This suggests the β1 subunit modulates the
interaction between lacosamide and the NaV1.2 α-subunit.
METHODS
CELL CULTURE
Chinese hamster ovary (CHO) cells stably expressing the rat
NaV1.2 channel (a gift from W.A. Catterall) were grown in fil-
ter sterilized DMEM/F12 (Invitrogen, Carlsbad, CA, USA) with
glutamine, supplemented with 2 g/LNaCHO3, 100 units/ml peni-
cillin, 0.01mg/ml streptomycin, 50mg/ml G418 at pH 7.4, 5%
FBS and maintained in a humidified environment at 37◦C with
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5% CO2. Cells were plated on glass cover slips at a density
conducive to single cell isolation.
TRANSFECTION
The stably expressing NaV1.2 cell line was transiently transfected
with either WT-β1 rat subunit (pBK/CMV vector) or the mutant
rat ortholog of the C121W-β1 (pBK/CMV), and enhanced green
fluorescent protein (eGFP) according to the PolyFect transfection
protocol (Invitrogen).
ELECTROPHYSIOLOGY
Whole-cell recordings were performed in an extracellular solu-
tion containing (in mM): 140NaCl, 4 KCl, 2 CaCl2, 1MgCl2, 10
HEPES. Solutions were adjusted to pH 7.4 with CsOH. Patch
pipettes were fabricated using a P-97 puller and borosilicate glass
(Sutter Instruments, CA, USA) using a Model P-1000 Puller
(Sutter Instruments), dipped in dental wax to reduce capaci-
tance, and thermally polished to a resistance of 1.0–1.5 M.
Pipette (intracellular) solution was composed of the following
(in mM): 120 CsF, 20 CsCl, 10NaCl, and 10 HEPES adjusted
to pH 7.4 with CsOH. Dimethyl sulfoxide (DMSO) was used
as solvent for lacosamide and diluted in bath solution at <
1:1000 (by volume) from stock to obtain a 100μM final drug
concentration. Stock lacosamide solution was pre-aliquoted in
extracellular solution. All recordings were made using an EPC-9
patch-clamp amplifier (HEKA Elektronik, Lambrecht, Germany)
digitized at 200 kHz via an ITC-16 interface (Instrutech, Great
Neck, NY, USA). Voltage clamping and data acquisition were con-
trolled using PatchMaster/FitMaster software (HEKA Elektronik,
Lambrecht, Germany) running on an Apple iMac. Current was
low-pass-filtered at 5 kHz. Leak subtraction was performed auto-
matically by software using a P/4 procedure following the test
pulse. Bath solution was maintained at 22◦C ± 0.2◦C or 34◦C ±
0.2◦C using a Peltier device controlled by an HCC-100A temper-
ature controller (Dagan, Minneapolis, MN, USA). Experiments
were not performed at higher temperatures because of inher-
ent instability of the temperature controller and cell membranes
beyond 34◦C.
Gigaohm seals were allowed to stabilize in the on-cell configu-
ration for 1min prior to establishing the whole-cell configuration.
We ensured that cells used for recordings had R-series <3.5M
for recordings. Series resistance compensation up to 80% was
used when necessary. All data were acquired >5min after attain-
ing the whole-cell configuration, and cells were allowed to
incubate 5min after drug application prior to data collection.
Before each protocol, themembrane potential was hyperpolarized
to −110mV to insure complete removal of both fast-inactivation
and slow-inactivation.
ANALYSIS
Analysis and graphing were done using FitMaster software
(HEKA Elektronik, Lambrecht, Germany) and Igor Pro
(Wavemetrics, Lake Oswego, OR, USA) with statistical infor-
mation derived using InStat (Graphpad Software Inc., San
Diego, CA, USA). All data acquisition and analysis programs
were run on an Apple iMac (Apple Computer, Cupertino, CA).
Exponential or Boltzmann fits were performed for individual
data sets to obtain means for time constants, apparent valence
(z), and midpoints of voltage-dependence (V1/2). Statistical
significance was accepted at p < 0.05 using Student’s unpaired
“t” tests with two-tailed p-values. All values reported are given as
means ± standard error of means.
VOLTAGE PROTOCOLS
Activation
To determine the voltage dependence of activation, we measured
the peak current amplitude at test pulse potentials ranging from
−80mV to+60mV in increments of +10mV for 20ms. Channel
conductance (G) was calculated from peak INa.
GNa = INa/V − ENa
whereGNa is conductance, INa is peak sodium current in response
to the command potential V, and ENa is the Nernst equilibrium
potential. Calculated values for conductance were fit with the
Boltzmann equation:
G/Gmax = 1/
(
1 + exp[−ze0
[
Vm − V1/2
]
/kT
])
where G/Gmax is normalized conductance amplitude, Vm is the
command potential, z is the apparent valence, e0 is the elementary
charge, V1/2 is the midpoint voltage, k is the Boltzmann constant,
and T is temperature in ◦K.
Steady-state fast inactivation
The voltage-dependence of fast inactivation was measured by
preconditioning the channels to a hyperpolarizing potential
of −130mV and then eliciting prepulse potentials that ranged
from −130 to +10mV in increments of 10mV for either 20ms
or 500ms, followed by a 10ms test pulse during which the voltage
was stepped to 0mV. Normalized current amplitude as a function
of voltage was fit using the Boltzmann equation:
I/Imax = 1/(1 + exp
(−ze0
(
VM − V1/2
)
/kT
)
where Imax is the maximum test pulse current amplitude.
Open-state fast inactivation
Time constants for open state fast-inactivation were derived by
fitting a single exponential function to the decay of current from
the peak to the end of the depolarizing stimulus.
Recovery from fast inactivation
Channels were fast-inactivated during a 20ms or 500ms depo-
larizing step to 0mV, and recovery was measured during a 19ms
test pulse to 0mV following a −110mV recovery pulse for dura-
tions between 0 and 1.024 s. Time constants of fast inactivation
recovery showed two components and were fit using a double
exponential equation:
I = Iss + α1exp(−t/τ1) + α2exp (−t/τ2)
where I is current amplitude, Iss is the plateau amplitude, α1 and
α2 are the amplitudes at time 0 for time constants τ1 and τ2, and
t is time.
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Steady-state slow inactivation
The voltage-dependence of slow inactivation was measured by
preconditioning the cells −130mV for 30 s. We then delivered
prepulse potentials from −130mV to +10mV, alternating with
every sweep, in increments of 20mV. After the prepulse, a 100ms
pulse at −130mV was applied to recover channels from fast
inactivation prior to a 20ms test pulse at 0mV. Peak current
amplitude during the test pulse was normalized to that measured
following the most negative prepulse, and plotted as a func-
tion of prepulse potential. Steady-state slow inactivation curves
were fit with the following modified Boltzmann equation that
takes into account changes in the steady-state probability of slow
inactivation:
I/Imax = (I1 − I2)/(1 + exp
(−ze0
(
Vm − V1/2
)
/kT
) + I2
where I/Imax is the maximum probability, I1 and I2 are maxi-
mum and minimum values in the fit, respectively, z is apparent
valence, e0 is the elementary charge, Vm is the prepulse potential,
V1/2 is the midpoint voltage of the steady-state slow inactiva-
tion curve, k is the Boltzmann constant, and T is the absolute
temperature.
Onset of slow inactivation
A 5ms test pulse to 0mV measured the rate of slow-inactivation
onset following a two-pulse protocol consisting of 0–64 s dura-
tions at the conditioning voltage (0mV) and a 100ms or 2 s
hyperpolarizing pulse to −110mV (“recovery pulse”). Time con-
stants of slow-inactivation onset as a function of time were fit
using a double exponential equation.
Recovery from slow inactivation
Slow inactivation was induced with either a 500ms or 8 s depo-
larizing pulse to 0mV, after which the membrane was hyperpo-
larized to −110mV for durations of 0.02–60 s and peak current
was tested with a 5ms pulse to 0mV. Time constants of slow inac-
tivation recovery, plotted as a function of time, were fit with a
double exponential equation.
RESULTS
ACTIVATION
Lacosamide (100μM) caused no significant effect on the volt-
age dependence of activation. There were no significant shifts in
the midpoint (V1/2) or apparent valence (z) at either elevated or
normal temperatures in the WT-β1 and the C121W-β1 subunits
(Table 1). Current traces from the four experimental conditions
are shown in Figure 1.
FAST INACTIVATION
Lacosamide did not cause significant shifts in the kinetics of open
state fast inactivation parameters in NaV1.2 co-expressed with
either WT-β1 or C121W-β1 (Table 2). We examined steady-state
fast inactivation with both 20ms and 500ms prepulse duration.
There were no statistically significant shifts in the midpoint or
apparent valence between control and 100μM lacosamide for
Table 1 | Activation parameters.
V 1/2 (mV) z (slope) n
22◦C
WT-β1 Control −19.4 ± 0.7 4.1 ± 0.2 12
WT-β1 Drug −19.2 ± 2.0 3.7 ± 0.2 6
C121W-β1 Control −16.0 ± 1.0 3.3 ± 0.1 10
C121W-β1 Drug −16.8 ± 1.2 3.5 ± 0.4 6
34◦C
WT-β1 Control −19.7 ± 0.4 6.1 ± 0.2 17
WT-β1 Drug −21.1 ± 0.5 6.6 ± 0.3 11
C121W-β1 Control −18.8 ± 0.3 7.1 ± 0.2 19
C121W-β1 Drug −21.5 ± 0.6 6.3 ± 0.4 9
FIGURE 1 | Macroscopic currents. Current amplitude plotted verses time duration (ms). These traces were elicited by a set of alternating test pulses that
range from −80mV to +60mV in increments of +10mV.
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Table 2 | Open-state fast inactivation.
τ −20mV (ms) τ −10mV (ms) τ 0mV (ms) τ 10mV (ms) τ 20mV (ms) n
22◦C
WT-β1 Control 1.29 ± 0.11 0.72 ± 0.05 0.51 ± 0.04 0.38 ± 0.03 0.34 ± 0.02 8
WT-β1 Drug 1.26 ± 0.16 0.70 ± 0.07 0.46 ± 0.04 0.36 ± 0.04 0.28 ± 0.02 7
C121W-β1 Control 1.03 ± 0.13 0.70 ± 0.07 0.52 ± 0.04 0.42 ± 0.05 0.39 ± 0.03 7
C121W-β1 Drug 1.09 ± 0.10 0.72 ± 0.04 0.54 ± 0.03 0.47 ± 0.03 0.39 ± 0.02 5
34◦C
WT-β1 Control 0.61 ± 0.04 0.41 ± 0.03 0.29 ± 0.02 0.23 ± 0.02 0.20 ± 0.02 14
WT-β1 Drug 0.55 ± 0.05 0.37 ± 0.02 0.28 ± 0.02 0.23 ± 0.02 0.19 ± 0.01 11
C121W-β1 Control 0.89 ± 0.06 0.57 ± 0.04 0.42 ± 0.02 0.34 ± 0.02 0.29 ± 0.02 18
C121W-β1 Drug 0.89 ± 0.06 0.66 ± 0.05 0.51 ± 0.04 0.41 ± 0.04 0.35 ± 0.03 13
FIGURE 2 | Steady-state fast inactivation. Normalized current is plotted
against a range of prepulse potentials (mV). Steady-state fast inactivation
was elicited by both 20ms prepulse durations (filled circles) and 500ms
prepulse durations (filled squares). For both WT at 22◦C and 34◦C (A,B)
and C121W at 22◦C and 34◦C (C,D). The means of control (shown in
black) were compared to 100μM Lacosamide (shown in red). In panel (D),
an inset shows the pulse protocol used to measure steady-state fast
inactivation.
WT-β1 at 22◦C with prepulse durations of 20ms (Figure 2A,
Table 3). At 34◦C there was a significant shift in the mid-
point value (Figure 2B, Table 3). However, there was no shift
in the apparent valence with drug perfusion. Stabilization of
steady-state fast inactivation was observed with 500ms prepulse
depolarizations. At both 22◦C and 34◦C, there were significant
hyperpolarizing shifts in the midpoint (V1/2) values with the
WT-β1 (Figures 2A,B, Table 3). There were no significant dif-
ferences in the apparent valence when comparing temperature
(Table 3).
In contrast, there were no significant shifts observed in the
V1/2 or apparent valence values of C121W-β1 with 100μM
lacosamide using 20ms or 500ms prepulse durations at 22◦C or
34◦C (Figures 2C,D and Table 3).
We examined the recovery kinetics of fast inactivation with
both 20ms and 500ms prepulse durations. Peak current ampli-
tudes in the second depolarizing pulse of a double-pulse protocol,
plotted as a function of interpulse duration, were fit with a double
exponential function. We compared the fast (τf) and slow (τs)
time constants and amplitudes, and the asymptote (y0) values.
There were no significant shifts in the kinetics of fast inactiva-
tion recovery at 22◦C and 34◦C with 20ms prepulse durations
(Figure 3, Table 4). With 500ms prepulses at 34◦C, there was a
significant decrease in the amplitude of the fast recovery compo-
nent with 100μM lacosamide and also a significant decrease in
the plateau y0 value (Table 4).
In contrast, we observed no statistically significant differences
in any of the fast inactivation recovery kinetic parameter at either
22◦C or 34◦C in the C121W-β1mutation (Figures 3C,D, Table 4)
with both 20ms and 500ms prepulse durations.
SLOW INACTIVATION
We examined onset kinetics of slow inactivation with
either 100ms or 2 s recovery pulse following conditioning
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Table 3 | Steady-state fast inactivation parameters.
Inactivation (20ms) Inactivation (500ms)
V 1/2 (mV) z (slope) n V 1/2 (mV) z (slope) n
22◦C
WT-β1 Control −55.7 ± 1.6 −2.7 ± 0.1 5 −68.7 ± 1.4a −3.7 ± 0.2 10
WT-β1 100 Drug −56.6 ± 1.6 −2.8 ± 0.1 6 −73.5 ± 1.3a −3.5 ± 0.3 5
C121W-β1 Control −56.0 ± 3.0 −2.4 ± 0.1 4 −66.1 ± 2.2 −3.8 ± 0.2 11
C121W-β1 Drug −53.4 ± 4.9 −2.2 ± 0.1 4 −68.7 ± 1.7 −3.8 ± 0.2 7
34◦C
WT-β1 Control −66.3 ± 0.3b −8.8 ± 0.3 7 −72.8 ± 0.5c −8.4 ± 0.5 7
WT-β1 Drug −70.0 ± 0.4b −10.3 ± 0.4 6 −76.5 ± 0.6c −9.8 ± 0.6 6
C121W-β1 Control −61.4 ± 0.5 −11.1 ± 0.4 7 −70.4 ± 0.6 −9.3 ± 0.5 7
C121W-β1 Drug −63.6 ± 0.7 −12.1 ± 0.7 6 −70.3 ± 0.4 −9.7 ± 0.3 6
aP < 0.05 vs. WT-β1 Control at 22◦C.
bP < 0.01 vs. WT-β1 Control at 34◦C.
cP < 0.05 vs. WT-β1 Control at 34◦C.
FIGURE 3 | Fast inactivation recovery. Normalized Current is plotted
against a range of recovery durations (ms). Filled circles shows fast
inactivation recovery elicited by 20ms prepulse durations; whereas closed
triangles represent prepulse durations of 500ms. For both WT at 22◦C and
34◦C (A,B) and C121W at 22◦C and 34◦C (C,D). The means of control
(shown in black) were compared to 100μM lacosamide (shown in red).
Panel (D) shows an inset of the double pulse protocol measuring fast
inactivation recovery.
depolarizations of varying durations. At 22◦C the changes
induced by 100μM lacosamide were not statistically signifi-
cant in either the C121W-β1or WT-β1 co-expressed channels
(Figures 4A,C, Table 5). Significant alterations of onset kinet-
ics were observed at 34◦C with the WT-β1 subunit. With
the 2 s recovery pulse we observed an increase in the ampli-
tude of the fast onset component as well as a decrease in the
plateau y0 value (Figure 4B, Table 5). This trend was also
observed for the 100ms recovery pulse, but turned out to be
not statistically significant. C121W-β1 co-expressed channels
demonstrated no significant changes in the onset kinetics with
drug perfusion at 34◦C with either recovery pulse duration
(Figure 4D, Table 5).
We next examined the voltage-dependence of steady-state slow
inactivation. We observed significant effects of lacosamide at
elevated and normal temperatures in the presence of the WT-
β1 subunit. At 22◦C there was a ∼7mV hyperpolarizing shift in
steady-state slow inactivation in 100μM lacosamide (Figure 5A,
Table 6). This hyperpolarized shift was exacerbated at 34◦C
(Figure 5B, Table 6). The maximum probability of steady-state
slow inactivation also increased significantly in the presence of the
drug at 34◦C (Table 6). C121W-β1 co-expressed channels exhib-
ited no significant shifts in the V1/2, apparent valence, or the
plateau values of steady-state slow inactivation at either 22◦C or
34◦C with the perfusion of 100μM lacosamide (Figures 5C,D,
Table 6).
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Table 4 | Fast inactivation recovery.
Recovery (20ms) Recovery (500ms)
τ1 (ms) A1 τ2 (ms) A2 y0 n τ1 (ms) A1 τ2 (ms) A2 y0 n
22◦C
WT-β1 Control 2.7 ± 0.3 0.82 ± 0.07 17.3 ± 9.5 0.15 ± 0.07 0.98 ± 0.01 5 3.7 ± 0.1a 0.48 ± 0.01 110.2 ± 10.1 0.21 ± 0.01 0.69 ± 0.01 5
WT-β1 Drug 1.6 ± 0.7 0.71 ± 0.07 3.6 ± 4.0 0.25 ± 0.07 0.97 ± 0.01 6 2.0 ± 0.1a 0.51 ± 0.02 140.5 ± 28.8 0.18 ± 0.01 0.69 ± 0.01 5
C121W-β1 Control 2.4 ± 0.4 0.83 ± 0.20 7.4 ± 7.9 0.12 ± 0.20 0.96 ± 0.01 4 3.3 ± 0.3 0.56 ± 0.02 133.7 ± 35.8 0.17 ± 0.02 0.73 ± 0.01 6
C121W-β1 Drug 1.9 ± 0.2 0.78 ± 0.09 8.5 ± 3.6 0.18 ± 0.09 0.97 ± 0.01 4 3.8 ± 0.3 0.52 ± 0.02 224.0 ± 53.5 0.23 ± 0.02 0.74 ± 0.02 5
34◦C
WT-β1 Control 1.8 ± 0.1 0.75 ± 0.04 17.0 ± 4.0 0.20 ± 0.04 0.98 ± 0.01 6 3.3 ± 0.3 0.36 ± 0.01b 207.0 ± 24.0 0.33 ± 0.01 0.71 ± 0.01b 7
WT-β1 Drug 2.1 ± 0.2 0.82 ± 0.03 23.0 ± 9.0 0.13 ± 0.03 0.99 ± 0.01 8 3.7 ± 0.3 0.20 ± 0.01b 285.0 ± 15.0 0.37 ± 0.01 0.61 ± 0.01b 6
C121W-β1 Control 2.5 ± 0.2 0.85 ± 0.03 40.0 ± 21.0 0.11 ± 0.03 0.98 ± 0.01 7 3.9 ± 0.4 0.51 ± 0.02 200.0 ± 44.0 0.26 ± 0.02 0.81 ± 0.02 7
C121W-β1 Drug 3.1 ± 0.3 0.73 ± 0.05 29.0 ± 9.0 0.21 ± 0.05 0.98 ± 0.01 8 4.2 ± 0.6 0.47 ± 0.03 184.0 ± 32.0 0.32 ± 0.03 0.82 ± 0.01 6
aP < 0.001 vs. WT-β1 100μM Lacosamide at 22◦C.
bP < 0.001 vs. WT-β1 100μM Lacosamide at 34◦C.
FIGURE 4 | Slow inactivation onset. Normalized Current is plotted
against a range of onset durations (s). We show two different recovery
pulse durations: 100ms (filled squares) and 2 s (filled circles) in control
(black) and 100μM lacosamide (red). For both WT at 22◦C and 34◦C
(A,B) and C121W at 22◦C and 34◦C (C,D). Inset in (D) shows the pulse
protocol.
We also measured recovery from slow inactivation and drug
block using both 500ms and 8 s conditioning depolarizing pulses.
At 22◦C we did not observe any significant differences in any of
the kinetic parameters of recovery with either 500ms or 8 s depo-
larization durations with WT-β1 or C121W-β1 subunits with
the addition 100μM lacosamide (Figures 6A,C, Table 7). WT-β1
but not C121W-β1 co-expressed channels demonstrated a sig-
nificant deceleration of recovery with drug perfusion at 34◦C
(Figures 6B,D, Table 7).
DISCUSSION
In this study we established the role of sodium channel β1 subunit
in modulating the effects of a physiologically relevant concen-
tration of lacosamide on the biophysical properties of the brain
sodium channel, NaV1.2. We also tested the functional effects
C121W, a mutation in the β1 subunit which causes GEFS+
phenotype (Wallace et al., 1998), on the ability of lacosamide to
inhibit sodium currents.
Similar to previous observations of Errington et al. (2008) and
Sheets et al. (2008), we found that lacosamide caused no signif-
icant changes in the voltage dependence of NaV1.2 activation or
kinetics of fast inactivation with either the WT-β1 or C121W-β1
subunits. Also there were no measurable differences in activation
between the WT and the mutant C121W-β1 subunits. This result
is consistent with findings of Qin et al. (2003) and Egri et al.
(2012), who reported no effect on activation upon co-expression
of the β1 subunit.
Lacosamide is postulated to be a slow inactivation-selective
drug (Errington et al., 2008; Sheets et al., 2008) that does not
affect fast inactivation mechanism but exerts its inhibitory effects
on the time scale of seconds, far slower than that for many other
“classic” anticonvulsants such as phenytoin, carbamazepine, and
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Table 5 | Slow inactivation onset.
Onset (100ms) Onset (2 s)
τ1 (s) A1 τ2 (s) A2 y0 τ1 (s) A1 τ2 (s) A2 y0 n
22◦C
WT-β1 Control 1.5 ± 0.3 0.47 ± 0.08 7.6 ± 2.3 0.23 ± 0.08 0.10 ± 0.01 1.48 ± 0.62 0.16 ± 0.03 25.8 ± 11.7 0.25 ± 0.03 0.57 ± 0.04 5
WT-β1 Drug 1.6 ± 0.1 0.48 ± 0.02 15.1 ± 4.2 0.14 ± 0.02 0.19 ± 0.07 1.03 ± 0.21 0.10 ± 0.01 23.9 ± 1.6 0.26 ± 0.01 0.67 ± 0.01 5
C121W-β1 Control 2.6 ± 0.2 0.68 ± 0.04 19.4 ± 13.7 0.10 ± 0.04 0.11 ± 0.01 3.35 ± 0.46 0.20 ± 0.02 33.7 ± 10.0 0.22 ± 0.01 0.57 ± 0.02 5
C121W-β1 Drug 2.3 ± 0.2 0.59 ± 0.04 16.2 ± 6.6 0.17 ± 0.04 0.09 ± 0.01 3.41 ± 0.60 0.14 ± 0.02 38.3 ± 9.8 0.27 ± 0.01 0.57 ± 0.03 7
34◦C
WT-β1 Control 0.59 ± 0.10 0.34 ± 0.04 4.2 ± 1.5 0.15 ± 0.04 0.03 ± 0.01 1.10 ± 0.20 0.19 ± 0.02a 25.0 ± 5.0 0.32 ± 0.02 0.34 ± 0.02b 8
WT-β1 Drug 0.73 ± 0.10 0.38 ± 0.01 5.4 ± 1.9 0.03 ± 0.01 0.00 ± 0.01 1.00 ± 0.20 0.28 ± 0.02a 19.0 ± 3.0 0.30 ± 0.02 0.22 ± 0.01b 6
C121W-β1 Control 1.60 ± 0.10 0.60 ± 0.03 19.0 ± 12.0 0.09 ± 0.02 0.03 ± 0.01 3.10 ± 0.80 0.16 ± 0.03 31.0 ± 8.0 0.36 ± 0.02 0.43 ± 0.03 6
C121W-β1 Drug 1.30 ± 0.10 0.50 ± 0.02 8.0 ± 2.0 0.20 ± 0.03 0.07 ± 0.01 1.70 ± 0.40 0.13 ± 0.02 31.0 ± 6.0 0.56 ± 0.02 0.49 ± 0.03 6
aP < 0.05 vs. WT-β1 100μM Lacosamide at 34◦C.
bP < 0.01 vs. WT-β1 100μM Lacosamide at 34◦C.
FIGURE 5 | Steady-state slow inactivation. Normalized Current is plotted
against the potential (mV). Control is shown in black circles and drug in red
triangles. For both WT at 22◦C and 34◦C (A,B) and C121W at 22◦C and 34◦C
(C,D). Panel (D) shows an inset of the pulse protocol used to measure slow
inactivation. The difference from the protocol used to measure steady-state
fast inactivation is that the prepulse duration is longer (50 s) and followed by a
brief recovery pulse that recovers channels from fast inactivation prior to the
test pulse.
Table 6 | Steady-state slow inactivation.
V 1/2 (mV) z (slope) plateau (y0) n
22◦C
WT-β1 Control −61.9 ± 2.1a −2.7 ± 0.4 0.21 ± 0.03 6
WT-β1 Drug −68.9 ± 2.5a −2.8 ± 0.4 0.22 ± 0.07 6
C121W-β1 Control −62.3 ± 2.4 −3.4 ± 0.5 0.08 ± 0.05 5
C121W-β1 Drug −60.7 ± 1.6 −2.7 ± 0.2 0.18 ± 0.03 8
34◦C
WT-β1 Control −70.2 ± 0.9b −7.4 ± 1.0 0.27 ± 0.03b 7
WT-β1 Drug −83.8 ± 0.8b −11.5 ± 0.7 0.12 ± 0.03b 9
C121W-β1 Control −73.9 ± 0.5 −7.6 ± 0.5 0.15 ± 0.02 7
C121W-β1 Drug −77.2 ± 0.5 −10.4 ± 0.4 0.10 ± 0.02 11
aP < 0.05 vs. WT-β1 Control at 22◦C.
bP < 0.001 vs. WT-β1 Control at 34◦C.
lamotrigine (Ragsdale et al., 1996; Ragsdale and Avoli, 1998).
Thus, Errington et al. (2008) showed an insignificant shift in
the steady-state fast inactivation curve with 100μM lacosamide
on N1E-115 neuroblastoma cells. Similarly, lacosamide had no
significant effect on the steady-state fast inactivation profile in
NaV1.7 or NaV1.3 (Sheets et al., 2008) expressed in HEK293 cells
in the absence of β1 subunits.
The results of our study generally corroborate the notion
of lacosamide’s specific interaction with the slow inactivation.
However, in the presence of the WT-β1 subunit we observed
that even relatively short conditioning pulses (500ms) are suf-
ficient to cause a measurable effect of 100μM lacosamide on
the voltage dependent availability of the channels (Figure 2A).
These findings are qualitatively similar to those of Uebachs et al.
(2010) who described the importance of the β1 subunit in
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FIGURE 6 | Slow inactivation recovery. Normalized Current is plotted over
the various recovery durations (s). Recovery was measured using both
500ms prepulse durations (closed circles) and also 8 s (closed squares).
Control (black) is compared to 100μM Lacosamide (red). For both WT at
22◦C and 34◦C (A,B) and C121W at 22◦C and 34◦C (C,D). Panel (D) shows a
pulse protocol inset used to measure slow inactivation recovery.
Table 7 | Slow Inactivation Recovery.
Recovery (500ms) Recovery (8 s)
τ1 (s) A1 τ2 (s) A2 y0 τ1 (s) A1 τ2 (s) A2 y0 n
22◦C
WT-1 Control 0.09 ± 0.02 0.19 ± 0.02 1.87 ± 0.68 0.12 ± 0.02 0.99 ± 0.01 0.38 ± 0.06 0.62 ± 0.05 5.89 ± 1.76 0.34 ± 0.05 1.01 ± 0.02 5
WT-1 Drug 0.13 ± 0.03 0.23 ± 0.03 2.31 ± 1.51 0.08 ± 0.03 1.01 ± 0.01 0.28 ± 0.07 0.64 ± 0.09 3.66 ± 1.95 0.26 ± 0.09 0.99 ± 0.02 5
C121W-1 Control 0.09 ± 0.06 0.12 ± 0.06 1.11 ± 1.19 0.09 ± 0.05 1.01 ± 0.01 0.49 ± 0.09 0.66 ± 0.06 9.98 ± 5.36 0.24 ± 0.05 1.00 ± 0.03 5
C121W-1 Drug 0.10 ± 0.06 0.13 ± 0.05 1.10 ± 0.73 0.12 ± 0.05 1.01 ± 0.01 0.41 ± 0.06 0.66 ± 0.05 5.58 ± 2.09 0.26 ± 0.05 1.00 ± 0.01 7
34◦C
WT-1 Control 0.16 ± 0.04a 0.27 ± 0.03a 2.3 ± 0.3b 0.32 ± 0.03c 0.98 ± 0.01 1.00 ± 0.20 0.58 ± 0.06 9.0 ± 2.0 0.38 ± 0.03c 0.96 ± 0.02 8
WT-1 Drug 0.51 ± 0.07a 0.44 ± 0.03a 10.0 ± 3.0b 0.22 ± 0.02c 0.98 ± 0.01 1.60 ± 0.40 0.42 ± 0.08 12.0 ± 2.0 0.57 ± 0.04c 0.98 ± 0.02 6
C121W-1 Control 0.16 ± 0.04 0.25 ± 0.02 2.9 ± 0.8 0.13 ± 0.02 1.00 ± 0.01 0.46 ± 0.09 0.60 ± 0.08 4.0 ± 1.0 0.41 ± 0.06 0.96 ± 0.02 6
C121W-1 Drug 0.12 ± 0.03 0.18 ± 0.02 1.8 ± 0.4 0.16 ± 0.02 0.98 ± 0.01 0.56 ± 0.08 0.62 ± 0.06 6.0 ± 2.0 0.29 ± 0.06 1.00 ± 0.01 7
aP < 0.001 vs. WT-β1 Control at 34◦C.
bP < 0.01 vs. WT-β1 Control at 34◦C.
cP < 0.05 vs. WT-β1 Control at 34◦C.
delimiting the sensitivity of NaV1.2 to another anticonvulsant,
carbamazepine.
Co-expression of the WT-β1 subunit induces multiple effects
on the kinetics of sodium channels, including accelerating fast
inactivation and recovery, stabilizing steady-state fast inactivation
(Tammaro et al., 2002; Aman et al., 2009; Webb et al., 2009;
Egri et al., 2012), and increasing the maximum probability
of slow inactivation (Vilin et al., 1999; Egri et al., 2012).
Elevated temperature further accelerates the channel kinetics
(Webb and Cannon, 2008; Thomas et al., 2009). As a result,
at 34◦C, channels enter inactivated states faster (Figure 2A
vs. B, C vs. D) and, even with relatively short conditioning
pulses, the effects of 100μM lacosamide become statistically
significant (Figure 2, Table 3). The trend seen in instantaneous
availability curves is further supported by lacosamide slow-
ing recovery after 500ms conditioning depolarization at 34◦C
(Figure 3B).
Longer depolarization pulses favor accumulation of chan-
nels into the slow inactivated state and thus enhance the effects
of 100μM lacosamide (Figures 4–6). Also, the stabilization of
steady-state slow inactivation by lacosamide is more pronounced
at 34◦C (Figure 5), suggesting that higher temperature also favors
slow inactivation.
The C121W mutation is located in the Ig-like domain of the
β1 subunit which is responsible for cell adhesion and aggrega-
tion, as well as α-β interactions resulting in modulation of the
voltage dependence and kinetics in NaV channels (Patino and
Isom, 2010). A putative structural consequence of this mutation
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is the disruption of the disulfide bond between residues 21
and 121. Functional implications include destabilization of fast
and slow inactivation leading to temperature-dependent hyper-
excitability of Nav1.2/C121W-β1 channels (Egri et al., 2012).
In the present study we demonstrate that the inhibitory effects
of 100μM lacosamide are lost when NaV1.2 is associated
with the mutant C121W-β1 subunit at both room temperature
and 34◦C.
In conclusion, our results concur with the principal notion
that lacosamide acts by stabilizing slow inactivation in Nav1.2.
Our results go beyond previous studies to suggest the WT-
β1 subunit indirectly modulates the efficacy of lacosamide by
regulating the stability of the slow inactivation in NaV1.2 in
a temperature dependent manner. The C121W-β1 mutation
disrupts the thermoprotective role of the β1 subunit on chan-
nel availability, which leads to hyper-excitability observed in
GEFS+ (Egri et al., 2012). This implies that patients carry-
ing C121W-β1 mutation may not benefit from treatment with
lacosamide.
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